

Congress of the United States  
Washington, DC 20515

January 8, 2015

Dr. Anthony Fauci  
Director  
National Institute of Allergy and Infectious Diseases  
National Institutes of Health  
9000 Rockville Pike  
Bethesda, MD 20892

Dear Dr. Fauci:


Thank you for appearing before the Subcommittee on Health on Wednesday, November 19, 2014, to testify at the hearing entitled "Examining Medical Product Development in the Wake of the Ebola Epidemic."

Pursuant to the Rules of the Committee on Energy and Commerce, the hearing record remains open for ten business days to permit Members to submit additional questions for the record, which are attached. The format of your responses to these questions should be as follows: (1) the name of the Member whose question you are addressing, (2) the complete text of the question you are addressing in bold, and (3) your answer to that question in plain text.

To facilitate the printing of the hearing record, please respond to these questions with a transmittal letter by the close of business on Thursday, January 22, 2015. Your responses should be mailed to Adrianna Simonelli, Legislative Clerk, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, D.C. 20515 and e-mailed in Word format to [Adrianna.Simonelli@mail.house.gov](mailto:Adrianna.Simonelli@mail.house.gov).

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,

  
Joseph R. Pitts  
Chairman  
Subcommittee on Health

cc: The Honorable Frank Pallone, Jr., Ranking Member, Subcommittee on Health

Attachment

## **Attachment—Additional Questions for the Record**

### **The Honorable Joseph R. Pitts**

1. As you know, there is an important public-private partnership that takes place between NIH/NIAID and the private sector with ongoing Ebola vaccine and drug research, as well as MCMs against other threats.
  - a. Please describe the importance of this partnership.
  - b. Please describe how the research at NIAID eventually moves to advanced development projects at BARDA?
  - c. Would you say this process has been successful? How could it be improved?
2. Please provide for the Committee with an overview of the Ebola vaccine candidates that are on the horizon and where they are in the process of moving into clinical trials and eventual mass vaccination campaigns in West Africa. As I understand it, your Institute has been funding the development of not only a monovalent Ebola vaccine, but also a multivalent Ebola/Marburg vaccine.
3. What initiatives are underway at the Department of Health and Human Services (HHS) to improve care for patients who are infected with Ebola today?
4. Given many of the well-reported supply challenges with mass-producing and manufacturing Ebola drug treatments, such as ZMapp and others, in the near-term pipeline of Ebola experimental and investigational treatments, do you see potential options that could have the drug supply available to actually treat thousands of Ebola patients in West Africa?
5. What is the role and pathway to join the global coalition of clinical trials for finding effective new experimental therapies in patients with Ebola Virus Disease in West Africa?
6. How would a treatment that focused on surviving the deadly complications of Ebola rather than the virus itself be tested in the coalition forming for clinical trials in West Africa?
7. For experimental treatments that are available today, what funds are being made available to rapidly test them to improve outcomes in patients in West Africa for patients with Ebola?

### **The Honorable Dr. Michael C. Burgess**

1. Please describe how the is the NIH communicating with the Department of Defense on research and development of vaccines, therapeutics and diagnostics.